High-Precision Genomic Engineering for Next-Generation Industrial Biotechnology. Yeast remains the premier eukaryotic workhorse for industrial fermentation, synthetic biology, and recombinant protein production. CD Biosynsis provides professional Yeast Genome Editing Services, utilizing cutting-edge CRISPR/Cas9 toolkits to perform scarless gene knockouts, multi-loci integrations, and metabolic pathway rewiring. Our platforms are optimized for both Saccharomyces cerevisiae and Pichia pastoris (Komagataella phaffii), enabling the rapid construction of high-performance strains for biofuels, pharmaceutical intermediates, and food-grade proteins.
Get a Technical QuoteOur platform integrates advanced CRISPR-mediated technologies with metabolic modeling to transform yeast into highly efficient microbial cell factories. We provide specialized toolkits for the most widely used industrial yeast species.
| Service Tier | Technical Strategy | Primary Application | Standard Deliverables |
|---|---|---|---|
| Markerless Knockout | CRISPR/Cas9 Allelic Replacement | Industrial fermentation & Biofuels | Verified null mutants + Growth data |
| Multi-Loci Integration | CrEdit (Multi-loci) Platform | Heterologous pathway assembly | Integrated strains + Pathway validation |
| Metabolic Rewiring | Synthetic Biology Chassis Optimization | High-value drugs (e.g., 6-MSA) | High-titer production strains + Titer report |
| Pichia Toolkit Engineering | Markerless Expression Cassettes | Recombinant protein & Food proteins | Optimized P. pastoris strains |
1. Target Design & Simulation
2. Vector Construction
3. Genome Execution
4. Phenotypic Screening
Identifying optimal integration sites and designing high-specificity gRNAs to maximize recombination efficiency.
Formal project proposal and Mutual NDA signing.
Developing customized CRISPR/Cas9 systems and donor DNA fragments for precise genomic interventions.
Assembling expression cassettes for markerless insertion into Pichia or Saccharomyces.
Performing multiplexed edits, including scarless deletions, promoter swapping, or multi-gene pathway assembly.
Ensuring nearly 100% integration efficiency using the CrEdit platform.
High-throughput characterization under industrial fermentation conditions and final verification via Sanger/WGS.
Final delivery of high-performance engineered strains and comprehensive data reports.
To deliver world-class results, our technical team continuously monitors and benchmarks our protocols against landmark research in the field. These studies demonstrate the versatility of engineered yeast.
Fermenting sugarcane molasses presents significant industrial challenges. By utilizing CRISPR/Cas9 to replace the PHO4 gene in Saccharomyces cerevisiae, research has demonstrated improved metabolic efficiency and higher stress tolerance. The resulting engineered strains exhibit significantly higher ethanol yields, providing a robust solution for large-scale biofuel production.
(Reference: Wu et al., 2020)
Converting yeast into a factory for high-value drug precursors (e.g., 6-methylsalicylic acid) requires complex rewiring. Benchmarks showcased the use of CRISPR/Cas9 to integrate multiple pathway genes and optimize enzyme activity. These engineered strains achieved a 10-fold increase in 6-MSA production compared to traditional strains, highlighting yeast’s potential in pharma R&D.
(Reference: Zhang et al., 2021)
Building heterologous pathways, such as beta-carotene biosynthesis, requires multiple gene integrations. Utilizing the CrEdit system, researchers achieved nearly 100% integration efficiency for three key genes at different loci without selection markers. This strategy drastically accelerates the construction of complex industrial strains.
(Reference: Sanchez et al., 2023)
For recombinant protein and food protein production, Pichia pastoris is a vital host. Advanced CRISPR/Cas9 toolkits now enable markerless integration of expression cassettes. This solves the traditional marker dependency problem, allowing for efficient integration of multi-gene pathways for the next generation of biomaterials.
(Reference: Li et al., 2025)
Ready to engineer your next-generation industrial yeast strain?
Contact Us1. What is the benefit of "markerless" integration for industrial yeast?
Markerless integration ensures the final strain contains no antibiotic resistance or auxotrophic markers. This is critical for industrial stability, avoids selective pressure, and is often a regulatory requirement for food-grade production.
2. Can you perform edits in my proprietary industrial yeast strain?
Yes. We have extensive experience adapting our CRISPR/Cas9 toolkits to diverse industrial and wild-type backgrounds. We work under strict NDAs to optimize your proprietary chassis.
3. How many genes can you integrate simultaneously in one round?
Utilizing our CrEdit platform, we can typically integrate 3 to 5 key genes into different genomic loci in a single round, significantly reducing the R&D timeline for complex pathways.
4. How do you verify the stability of the engineered integrated genes?
We perform long-term stability trials (e.g., >50 generations) and use Whole Genome Sequencing (WGS) to ensure the integrated pathways are maintained without genomic rearrangements.
5. Is the CRISPR/Cas9 machinery removed from the final production strain?
Yes. We utilize transient expression systems or specialized curing protocols to ensure that all CRISPR components are removed after the editing is complete, leaving a clean engineered strain without foreign DNA footprints.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.